Polygenic risk scores (PRS) did not predict the development of cannabis use disorder (CUD) in patients with schizophrenia and other psychiatric disorders, according to results from a study published in Psychological Medicine.
Researchers conducted a case-control study to examine the associations between PRS for schizophrenia and other mental disorders with the development of CUD. The retrospective analysis included 3 groups (N=88,637): patients with schizophrenia (n=3533; 55.9% men; mean age of onset, 21.5 years), patients with other mental disorders (n=56,393; 53.9% men; mean age of onset, 15.6 years), and nonpsychiatric control patients (n=28,711; 50.9% men). Data were obtained from iPSYCH data set, which combines Danish registry information with genetic data collected from dried neonatal bloodspots. PRS exposures of interest were autism spectrum disorder, anorexia nervosa, attention-deficit/hyperactivity disorder (ADHD), and schizophrenia; the key outcome of interest was diagnosis of CUD.